ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2507

Dactylitis and Enthesitis Predict Uveitis in Large Axial Spondyloarthropathy Cohort

Gillian Fitzgerald1, Phil Gallagher2, Catherine Sullivan3, Killian O Rourke4, Claire Sheehy5, Frances Stafford6, Carmel Silke7, Muhammad Haroon8, Ronan Mullan9, Sandy Fraser10, Grainne Murphy11, Shawn Chavrimootoo12, Oliver FitzGerald13 and Finbar O' Shea14, 1Rheumatology, St James's Hospital, Dublin 8, Ireland, 2St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, 3ASRI, Dublin, Ireland, Cork, Ireland, 4Rheumatology, Midlands Regional Hospital, Tullamore, Co Offaly, Ireland, 5Rheumatology, University Hospital Waterford, Waterford, Ireland, 6Rheumatology, Blackrock Clinic, Co Dublin, Ireland, 7Rheumatology, Sligo University Hospital, Sligo, Ireland, 8Rheumatology, Kerry General Hospital, Co Kerry, Ireland, 9Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, 10Department of Rheumatology, University Hospitals Limerick, Ireland, Limerick, Ireland, 11Rheumatology, Cork University Hospital, Cork, Ireland, 12Rheumatology, Our Lady's Hospital, Co Meath, Ireland, 13ASRI, Dublin, Ireland, Dublin, Ireland, 14St Jame, Dublin, Ireland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Axial spondyloarthritis and uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

ASRI (Ankylosing Spondylitis Registry of Ireland) is a national registry, designed to provide descriptive epidemiological data on the axial spondyloarthropathy (axSpA) population of Ireland. Uveitis is a common extra-articular manifestation in patients with axSpA. The exact prevalence and associated characteristics are not clearly defined in the literature. The aim of this study was to determine the prevalence of uveitis in a large axSpA cohort and identify associated characteristics.

Methods:

Patients enrolled in ASRI from 2013 until June 2017 were included in this study. A standardised detailed clinical assessment is performed on each patient at their inclusion. Structured interviews provide patient-reported data, including the presence of previous diagnosis of uveitis. Disease activity is assessed by Bath AS Disease Activity Index (BASDAI), spinal mobility by Bath AS Metrology Index (BASMI), function by the Bath AS Functional Index (BASFI) and Health Assessment Questionnaire (HAQ) and quality of life by AS Quality of Life (ASQoL). Statistical analysis is performed using SPSS.

Results:

As of June 2017, 683 patients have been entered in the database: 77% (n=526) male, mean age 45.9 years (SD 12.4), mean disease duration 19 years (SD 12.2), mean delay to diagnosis 8.6 years (SD 8.1), 78.8% fulfil modified New York criteria. Mean BASDAI is 3.9 (SD 2.5), BASMI is 3.6 (SD 2.5), BASFI is 3.6 (SD 2.7), HAQ is 0.52 (SD 0.52) and ASQoL is 6.4 (SD 5.5). HLA-B27 status is available for 74.1% (n=506) of the cohort: 92.7% of these are HLA-B27 positive.

The prevalence of uveitis in this cohort is 36.5%. With regards to other extra-articular manifestations, 6.9% have dactylitis, 18.3% have psoriasis, 9.2% have inflammatory bowel disease, 17.6% have enthesitis and 34.1% have peripheral arthritis.

Patients with uveitis are older (47 v 45 years, p=0.04) and have a longer duration of axial symptoms (21.7 v 17.3 years, p<0.01). There is no significant difference in markers of disease severity. Patients with uveitis have a higher prevalence of dactylitis (11.6% v 4.3%, p<0.01), enthesitis (25.9% v 13.5%, p<0.01), hypertension (26.1% v 18.6%, p=0.02) and HLA-B27 positivity (95.9% v 90.4%, p=0.02). There is a lower prevalence of smoking (22.2% v 32.2%, p=0.01) in patients with uveitis. Use of biologics is similar in patients with and without uveitis (30.7% v 26.8%, p=0.3). There is no difference in the use of NSAIDs (54.8% v 48.4%, p=0.1). There is a trend towards lower prevalence of IBD (12.1% v 7.6%, p=0.06) in patients with uveitis.

In multivariable regression analysis, disease duration, dactylitis and enthesitis are independently associated with the presence of uveitis, with dactylitis the strongest predictor (OR 3.2, 95% CI 1.5-6.8, p<0.01), followed by enthesitis (OR 1.8, 95% CI 1.1-2.9, p=0.02).

Conclusion:

In this axSpA cohort, 36.5% of patients have ever had an episode of uveitis. Uveitis is independently associated with dactylitis, enthesitis and longer disease duration. There is a higher prevalence of smokers in patients without uveitis.


Disclosure: G. Fitzgerald, Abbvie, 9; P. Gallagher, None; C. Sullivan, None; K. O Rourke, None; C. Sheehy, None; F. Stafford, None; C. Silke, None; M. Haroon, None; R. Mullan, None; S. Fraser, None; G. Murphy, None; S. Chavrimootoo, None; O. FitzGerald, Pfizer, Abbvie, BMS, Novartis, UCB, Janssen, Celgene and Lilly, 2; F. O' Shea, None.

To cite this abstract in AMA style:

Fitzgerald G, Gallagher P, Sullivan C, O Rourke K, Sheehy C, Stafford F, Silke C, Haroon M, Mullan R, Fraser S, Murphy G, Chavrimootoo S, FitzGerald O, O' Shea F. Dactylitis and Enthesitis Predict Uveitis in Large Axial Spondyloarthropathy Cohort [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/dactylitis-and-enthesitis-predict-uveitis-in-large-axial-spondyloarthropathy-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dactylitis-and-enthesitis-predict-uveitis-in-large-axial-spondyloarthropathy-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology